- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04285034
Cardiovascular Function and Ribavirin PK/PD in Lassa Fever in Lassa Fever
Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Lassa Fever Patients in Nigeria: a Prospective Observational Cohort Study
Arenaviruses are included in the World Health Organisation R&D Blueprint list of high priority pathogens, since this virus group includes several epidemic-prone highly pathogenic viruses for which there are inadequate diagnostic, therapeutic, and preventative interventions. Junin, Machupo, Guanarito, Sabia, Lujo, and Lassa virus can all cause a viral haemorrhagic fever with high case fatality in hospitalised cases. Lassa fever is the most common severe arenavirus disease and is endemic across many low and middle income countries in West Africa, with an estimated 37.7 million people in 14 countries living in areas at risk of Lassa virus. Despite the discovery of Lassa virus in 1972 and an estimated 300,000 cases and 5000-10,000 deaths annually, there remain gaps in our understanding of the natural history of disease and in the availability of evidence based interventions.
The protocol has two components. Sites may implement one or both components.
- Cardiovascular function in Lassa fever: Lassa fever in humans is often described in the literature as being characterized by vascular leak and shock in the terminal phase, this being the main pathway to death. Whilst animal data supports this, there are very limited data in humans. One of the main aims of this study therefore is to characterize cardiovascular function in patients with Lassa fever, with the ultimate goal of informing future trials of supportive or therapeutic strategies to improve vascular leak.
- Ribavirin pharmacokinetics and pharmacodynamics: The recommended treatment for Lassa is ribavirin, but its efficacy has not been established in randomized controlled trials and its mechanism of action is not fully understood. There are very limited PK data on ribavirin in patients with Lassa fever and the optimal dose of ribavirin for an RCT has not been established. Furthermore, there are various hypothesized mechanisms of action of ribavirin, none of which have been investigated in humans with Lassa fever. Therefore, further aims of this study are to characterize the PK of ribavirin and ribavirin metabolites (RMP, RDP, RTP) in Lassa fever patients and to identify potential mechanisms of action ribavirin in Lassa fever. Understanding Ribavirin's mechanism of action in Lassa fever is important for the optimal design of a future RCT.
Study Overview
Status
Conditions
Detailed Description
Summary of cardiovascular function study Lassa fever carries a treated mortality in hospitalized patients of up to 30%. Lassa fever is often described as being characterized by vascular leak and shock in the terminal phase, but, whilst animal data supports this, there are limited data in humans. A further aim of this study therefore is to characterize cardiovascular function in patients with Lassa fever, with the ultimate goal of informing future trials of supportive or therapeutic strategies.
Summary of ribavirin pharmacokinetics and pharmacodynamics sub-study Lassa fever carries a treated mortality in hospitalized patients of up to 30% in Nigeria. Ribavirin is the current standard of care. However, the efficacy of ribavirin has not been established in RCTs. There is very limited PK data on ribavirin in patients with Lassa fever and the optimal dose of ribavirin for an RCT is unknown. The aim of this study is to characterize the PK of ribavirin in Lassa fever, and identify any associations between ribavirin PK parameters and viral load and markers of inflammatory status.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ondo State
-
Owo, Ondo State, Nigeria, PMB 1053
- Owo Federal Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Cardiovascular Study:
Inclusion Criteria:
- Suspected or RT-PCR confirmed Lassa fever diagnosis
- Aged 10 years or above
Exclusion Criteria:
• None
Ribavirin PK/PD study
Inclusion Criteria:
- Suspected or RT-PCR confirmed Lassa fever diagnosis
- Patient will receive ribavirin therapy
- Aged 10 years or above
Exclusion Criteria:
• None
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Ribavirin only
Patients will receive ribavirin in accordance with Nigerian treatment guidelines. Patients will either receive the McCormick regimen or the Irrua regimen. PK blood tests will be done on Day 1,2,5,6,10,11,12,13, discharge; Paxgene RNA blood test on day 1, 3, 5, discharge Haematocrit finger prick test on day 1,2, 5, 6, 10, discharge |
Cardiocascular study only
Cardiac tests (NICAS (daily), ECG (Day 1, 5, 10, discharge), Echocardiogram (Day 1, 5, discharge), Ultrasound (Day 1, 3, 5, 7, 10), Endopat (Day 1 and discharge)) will be done throughout; Haematocrit finger prick test daily PAXgene RNA blood test on day 1, 5, discharge
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiovascular
Time Frame: through study completion, an average of 2 weeks
|
Mean Arterial Pressure is less than 65mmHg or Systolic Blood Pressure is less than 90mmgHg or pulse pressure < 20mmHg
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacokinetics
Time Frame: through study completion, an average of 2 weeks
|
Proportion of patients with ribavirin CMIN above the IC90 at > 80% of measured CMIN during therapy
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacodynamics
Time Frame: 5 days
|
Change in Lassa virus Viral Load from baseline to day 5
|
5 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiovascular
Time Frame: through study completion, an average of 2 weeks
|
To identify the frequency of shock
|
through study completion, an average of 2 weeks
|
Cardiovascular
Time Frame: through study completion, an average of 2 weeks
|
To identify the frequency of persistent shock
|
through study completion, an average of 2 weeks
|
Cardiovascular
Time Frame: through study completion, an average of 2 weeks
|
To identify the frequency of respiratory distress
|
through study completion, an average of 2 weeks
|
Cardiovascular
Time Frame: through study completion, an average of 2 weeks
|
To identify the frequency of shock and respiratory distress
|
through study completion, an average of 2 weeks
|
Cardiovascular
Time Frame: through study completion, an average of 2 weeks
|
To identify the frequency of Death
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacokinetics
Time Frame: through study completion, an average of 2 weeks
|
Proportion of patients with ribavirin CMIN above the IC50 at all measured CMIN during therapy
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacokinetics
Time Frame: through study completion, an average of 2 weeks
|
Duration of time that ribavirin levels are above the IC90 and IC50
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacokinetics
Time Frame: through study completion, an average of 2 weeks
|
Calculation of AUC [AUC∞ and AUCLAST] (ribavirin, ribavirin metabolites)
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacokinetics
Time Frame: through study completion, an average of 2 weeks
|
Calculation of CMAX (ribavirin, ribavirin metabolites)
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacokinetics
Time Frame: through study completion, an average of 2 weeks
|
Calculation of CMIN (ribavirin, ribavirin metabolites)
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacokinetics
Time Frame: through study completion, an average of 2 weeks
|
Calculation of T1/2 (ribavirin, ribavirin metabolites)
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacokinetics
Time Frame: through study completion, an average of 2 weeks
|
Volume of distribution (ribavirin, ribavirin metabolites)
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacokinetics
Time Frame: through study completion, an average of 2 weeks
|
Calculation of Clearance (ribavirin, ribavirin metabolites)
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacodynamics
Time Frame: 10 days
|
Change in Lassa virus Viral Load from baseline to day 3 and day 10
|
10 days
|
Ribavirin Pharmacodynamics
Time Frame: 10 days
|
Change in AST, ALT concentrations from baseline to day 3, 5, 10
|
10 days
|
Ribavirin Pharmacodynamics
Time Frame: 10 days
|
Change in eGFR from baseline to day 3, 5, 10
|
10 days
|
Ribavirin Pharmacodynamics
Time Frame: 10 days
|
Change in Haemoglobin from baseline to day 5, 10
|
10 days
|
Ribavirin Pharmacodynamics
Time Frame: 5 days
|
Change in ISG expression from baseline to day 3, 5
|
5 days
|
Ribavirin Pharmacodynamics
Time Frame: through study completion, an average of 2 weeks
|
Time to negative blood RT-PCR for Lassa virus
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacodynamics
Time Frame: through study completion, an average of 2 weeks
|
Requirement for blood transfusion during hospitalisation
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacodynamics
Time Frame: through study completion, an average of 2 weeks
|
Reaching KDIGO stage 3 during hospitalisation
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacodynamics
Time Frame: through study completion, an average of 2 weeks
|
Requirement for dialysis during hospitalisation
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacodynamics
Time Frame: through study completion, an average of 2 weeks
|
Duration of hospitalisation
|
through study completion, an average of 2 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiovascular Explanatory
Time Frame: through study completion, an average of 2 weeks
|
To identify the frequency of vascular leak
|
through study completion, an average of 2 weeks
|
Cardiovascular Explanatory
Time Frame: through study completion, an average of 2 weeks
|
To identify the frequency of cardiac function
|
through study completion, an average of 2 weeks
|
Cardiovascular Explanatory
Time Frame: through study completion, an average of 2 weeks
|
To identify the frequency of total peripheral resistance
|
through study completion, an average of 2 weeks
|
Cardiovascular Explanatory
Time Frame: through study completion, an average of 2 weeks
|
To identify the frequency of total body water
|
through study completion, an average of 2 weeks
|
Cardiovascular Explanatory
Time Frame: through study completion, an average of 2 weeks
|
To identify the frequency of Reactive hyperaemic index
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacokinetics Explanatory
Time Frame: through study completion, an average of 2 weeks
|
Age
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacokinetics Explanatory
Time Frame: through study completion, an average of 2 weeks
|
Gender
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacokinetics Explanatory
Time Frame: through study completion, an average of 2 weeks
|
Calculation of eGFR
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacokinetics Explanatory
Time Frame: through study completion, an average of 2 weeks
|
Calculation of Total body water
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacokinetics Explanatory
Time Frame: through study completion, an average of 2 weeks
|
ITPA, SLC28 gene polymorphisms
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacodynamics Explanatory
Time Frame: through study completion, an average of 2 weeks
|
Calculation of AUC [AUC∞ and AUCLAST]
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacodynamics Explanatory
Time Frame: through study completion, an average of 2 weeks
|
Calculation of CMAX
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacodynamics Explanatory
Time Frame: through study completion, an average of 2 weeks
|
Calculation of CMIN
|
through study completion, an average of 2 weeks
|
Ribavirin Pharmacodynamics Explanatory
Time Frame: through study completion, an average of 2 weeks
|
ITPA, IL28B and SLC28/29 gene polymorphisms
|
through study completion, an average of 2 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 04-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lassa Fever
-
National Institute of Allergy and Infectious Diseases...CompletedLassa Virus InfectionMali
-
Arisan Therapeutics, Inc.United States Department of Defense; Battelle Memorial Institute; The Defense...RecruitingLassa Virus InfectionUnited States
-
International AIDS Vaccine InitiativeBrigham and Women's Hospital; George Washington University; Redemption Hospital; East-West Medical Research InstituteActive, not recruitingLassa Fever | Lassa Virus InfectionUnited States, Liberia
-
Themis Bioscience GmbHAssign Data Management and Biostatistics GmbH; Coalition for Epidemic Preparedness... and other collaboratorsCompleted
-
Bernhard Nocht Institute for Tropical MedicineInstitut National de la Santé Et de la Recherche Médicale, France; University... and other collaboratorsCompleted
-
Bernhard Nocht Institute for Tropical MedicineNot yet recruiting
-
International AIDS Vaccine InitiativeCoalition for Epidemic Preparedness InnovationsRecruitingLassa FeverGhana, Liberia, Nigeria
-
University of OxfordLondon School of Hygiene and Tropical Medicine; Public Health England; National... and other collaboratorsTerminated
-
Irrua Specialist Teaching HospitalUniversity of Bordeaux; Médecins Sans Frontières, Belgium; ANRS, Emerging Infectious... and other collaboratorsNot yet recruitingLassa Fever
-
National Institute of Allergy and Infectious Diseases...Recruiting